Patents by Inventor Steve Roffler

Steve Roffler has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10995126
    Abstract: Described herein are an immunogenic peptide containing the sequence of CLDSLGQWN (SEQ ID NO:2) and a method of using the peptide for treating cancer.
    Type: Grant
    Filed: May 3, 2017
    Date of Patent: May 4, 2021
    Assignees: National Health Research Institutes, Academia Sinica
    Inventors: Shih-Jen Liu, Hsin-Wei Chen, Steve Roffler, Ming-Hsi Huang, Chih-Hsiang Leng
  • Patent number: 10912832
    Abstract: Disclosed herein is a multiple drugs delivery system and its uses in treating diseases. The multiple drugs delivery system includes, an anti-PEG antibody for directing the PEGylated therapeutic to the treatment site; and a hydrogel for retaining the anti-PEG antibody and/or the PEGylated therapeutic at the treatment site for at least 3 days. The hydrogel is selected from the group consisting of hyaluronan (HA) or a derivative of HA, collagen, gelatin, fibronectin, fibrinogen, alginate, chitosan, and a synthetic biocompatible polymer. The anti-PEG antibody and the hydrogel are present in the mixture in a ratio from about 1:1 (v/v) to 1:100 (v/v). At least two dosages of the PEGylated therapeutic, which may be the same or different, are administered to the subject, with each dosage being given at about 1 hour to about 1 week apart. Accordingly, a novel method of treating a subject having cancer or ischemia disease is also provided.
    Type: Grant
    Filed: November 27, 2019
    Date of Patent: February 9, 2021
    Assignee: ACADEMIA SINICA
    Inventors: Patrick C. H. Hsieh, Pei-Jung Wu, Steve Roffler, Bill Cheng
  • Publication number: 20200140572
    Abstract: A monomeric bispecific polyethylene glycol (PEG) engager that includes an anti-PEG Fab fused to a disulfide stabilized scFv that specifically binds to a cell surface antigen. The PEG engager, in the absence of PEG, remains monomeric upon binding to the cell surface antigen on a cell and remains on the surface of the cell. Also provided is a method for treating cancer by administering a PEG engager followed by a PEGylated anti-cancer agent. A kit that contains a PEG engager and a PEGylated anti-cancer agent is also disclosed. Further disclosed are methods for imaging cells and diagnosing cancer by administering a PEG engager followed by a PEGylated imaging agent. Another kit is provided that includes the PEG engager and the PEGylated imaging agent.
    Type: Application
    Filed: May 9, 2018
    Publication date: May 7, 2020
    Applicants: KAOHSIUNG MEDICAL UNIVERSITY, ACADEMIA SINICA
    Inventors: Steve ROFFLER, Tian-Lu Cheng, Yu-Cheng Su, Kuo-Hsiang Chuang
  • Publication number: 20200108143
    Abstract: Disclosed herein is a multiple drugs delivery system and its uses in treating diseases. The multiple drugs delivery system includes, an anti-PEG antibody for directing the PEGylated therapeutic to the treatment site; and a hydrogel for retaining the anti-PEG antibody and/or the PEGylated therapeutic at the treatment site for at least 3 days. The hydrogel is selected from the group consisting of hyaluronan (HA) or a derivative of HA, collagen, gelatin, fibronectin, fibrinogen, alginate, chitosan, and a synthetic biocompatible polymer. The anti-PEG antibody and the hydrogel are present in the mixture in a ratio from about 1:1 (v/v) to 1:100 (v/v). At least two dosages of the PEGylated therapeutic, which may be the same or different, are administered to the subject, with each dosage being given at about 1 hour to about 1 week apart. Accordingly, a novel method of treating a subject having cancer or ischemia disease is also provided.
    Type: Application
    Filed: November 27, 2019
    Publication date: April 9, 2020
    Inventors: Patrick C.H. HSIEH, Pei-Jung WU, Steve ROFFLER, Bill CHENG
  • Patent number: 10604747
    Abstract: An engineered enzyme, comprising an amino acid sequence that is at least 80% identical to the amino acid sequence of a human beta-glucuronidase, wherein the engineered enzyme exhibits a higher level of alpha-iduronidase enzymatic activity as compared to the human beta-glucuronidase.
    Type: Grant
    Filed: August 5, 2016
    Date of Patent: March 31, 2020
    Assignee: Academia Sinica
    Inventors: Steve Roffler, Huai-Yao Chuang
  • Patent number: 10532097
    Abstract: Disclosed herein is a multiple drugs delivery system and its uses in treating diseases. The multiple drugs delivery system includes, an anti-PEG antibody for directing the PEGylated therapeutic to the treatment site; and a hydrogel for retaining the anti-PEG antibody and/or the PEGylated therapeutic at the treatment site for at least 3 days. The hydrogel is selected from the group consisting of hyaluronan (HA) or a derivative of HA, collagen, gelatin, fibronectin, fibrinogen, alginate, chitosan, and a synthetic biocompatible polymer. The anti-PEG antibody and the hydrogel are present in the mixture in a ratio from about 1:1 (v/v) to 1:100 (v/v). At least two dosages of the PEGylated therapeutic, which may be the same or different, are administered to the subject, with each dosage being given at about 1 hour to about 1 week apart. Accordingly, a novel method of treating a subject having cancer or ischemic disease is also provided.
    Type: Grant
    Filed: July 10, 2015
    Date of Patent: January 14, 2020
    Assignee: Academia Sinica
    Inventors: Patrick C. H. Hsieh, Pei-Jung Wu, Steve Roffler, Bill Cheng
  • Publication number: 20190135883
    Abstract: Described herein are an immunogenic peptide containing the sequence of CLDSLGQWN (SEQ ID NO:2) and a method of using the peptide for treating cancer.
    Type: Application
    Filed: May 3, 2017
    Publication date: May 9, 2019
    Inventors: Shih-Jen Liu, Hsin-Wei Chen, Steve Roffler, Ming-Hsi Huang, Chih-Hsiang Leng
  • Patent number: 10180433
    Abstract: The present invention is related to a method for detecting a protein comprising: (1) providing a fusion protein, wherein the fusion protein comprises the protein which is fused with a secondary antibody detected protein tag, wherein the secondary antibody detected protein tag comprises at least one epitope selected from the Fc region of at least one primary antibody which is capable of being detected by a corresponding secondary antibody; (2) contacting the fusion protein with a secondary antibody which binds to the secondary antibody detected protein tag to form a protein/antibody complex; and (3) detecting the protein/antibody complex.
    Type: Grant
    Filed: August 23, 2016
    Date of Patent: January 15, 2019
    Assignee: KAOHSIUNG MEDICAL UNIVERSITY
    Inventors: Tian-Lu Cheng, Steve Roffler, Wen-Wei Lin, I-Ju Chen
  • Publication number: 20180346896
    Abstract: An engineered enzyme, comprising an amino acid sequence that is at least 80% identical to the amino acid sequence of a human beta-glucuronidase, wherein the engineered enzyme exhibits a higher level of alpha-iduronidase enzymatic activity as compared to the human beta-glucuronidase.
    Type: Application
    Filed: August 5, 2016
    Publication date: December 6, 2018
    Applicant: Academia Sinica
    Inventors: Steve Roffler, Huai-Yao Chuang
  • Publication number: 20170173154
    Abstract: Disclosed herein is a multiple drugs delivery system and its uses in treating diseases. The multiple drugs delivery system includes, an anti-PEG antibody for directing the PEGylated therapeutic to the treatment site; and a hydrogel for retaining the anti-PEG antibody and/or the PEGylated therapeutic at the treatment site for at least 3 days. The hydrogel is selected from the group consisting of hyaluronan (HA) or a derivative of HA, collagen, gelatin, fibronectin, fibrinogen, alginate, chitosan, and a synthetic biocompatible polymer. The anti-PEG antibody and the hydrogel are present in the mixture in a ratio from about 1:1 (v/v) to 1:100 (v/v). At least two dosages of the PEGylated therapeutic, which may be the same or different, are administered to the subject, with each dosage being given at about 1 hour to about 1 week apart. Accordingly, a novel method of treating a subject having cancer or ischemic disease is also provided.
    Type: Application
    Filed: July 10, 2015
    Publication date: June 22, 2017
    Applicant: Academia Sinica
    Inventors: Patrick Ch HSIEH, Pei-Jung WU, Steve ROFFLER, Bill CHENG
  • Publication number: 20160356784
    Abstract: The present invention is related to a method for detecting a protein comprising: (1) providing a fusion protein, wherein the fusion protein comprises the protein which is fused with a secondary antibody detected protein tag, wherein the secondary antibody detected protein tag comprises at least one epitope selected from the Fc region of at least one primary antibody which is capable of being detected by a corresponding secondary antibody; (2) contacting the fusion protein with a secondary antibody which binds to the secondary antibody detected protein tag to form a protein/antibody complex; and (3) detecting the protein/antibody complex.
    Type: Application
    Filed: August 23, 2016
    Publication date: December 8, 2016
    Applicant: KAOHSIUNG MEDICAL UNIVERSITY
    Inventors: TIAN-LU CHENG, Steve ROFFLER, WEN-WEI LIN, I-JU CHEN
  • Patent number: 9458243
    Abstract: A method of preparing an epitope for a secondary antibody detected protein tag, comprising: constructing a expressing vector, comprising a nucleotide sequence for encoding the secondary antibody detected protein tag comprising at least one epitope selected from at least one primary antibody which is detected by corresponding secondary antibody; expressing the vector in a host cell; and obtaining the secondary antibody detected protein tag which is expressed in the host cell. Further, a method for constructing a protein molecular weight marker ladder, comprising constructing a plurality of recombinant protein tags with different molecular weights, wherein each the recombinant protein tag comprises at least one epitope of primary antibody. Besides, a secondary antibody detected protein tag comprises at least two peptide sequences of epitopes selected from primary antibodies of at least two different species.
    Type: Grant
    Filed: November 6, 2014
    Date of Patent: October 4, 2016
    Assignee: Kaohsiung Medical University
    Inventors: Tian-Lu Cheng, Steve Roffler, Wen-Wei Lin, I-Ju Chen
  • Publication number: 20150315265
    Abstract: A method of preparing an epitope for a secondary antibody detected protein tag, comprising: constructing a expressing vector, comprising a nucleotide sequence for encoding the secondary antibody detected protein tag comprising at least one epitope selected from at least one primary antibody which is detected by corresponding secondary antibody; expressing the vector in a host cell; and obtaining the secondary antibody detected protein tag which is expressed in the host cell. Further, a method for constructing a protein molecular weight marker ladder, comprising constructing a plurality of recombinant protein tags with different molecular weights, wherein each the recombinant protein tag comprises at least one epitope of primary antibody. Besides, a secondary antibody detected protein tag comprises at least two peptide sequences of epitopes selected from primary antibodies of at least two different species.
    Type: Application
    Filed: November 6, 2014
    Publication date: November 5, 2015
    Applicant: KAOHSIUNG MEDICAL UNIVERSITY
    Inventors: TIAN-LU CHENG, Steve ROFFLER, WEN-WEI LIN, I-JU CHEN
  • Patent number: 8491891
    Abstract: A number of human beta-glucuronidase variants having higher enzymatic activity at physiological pH as compared with wild-type beta-glucuronidase and uses thereof in prodrug therapy. Also disclosed herein is a method for identifying enzyme variants having elevated enzymatic activity using a mammalian surface display system.
    Type: Grant
    Filed: November 25, 2009
    Date of Patent: July 23, 2013
    Assignee: Academia Sinica
    Inventors: Steve Roffler, Chia-Hung Wu, Wolfgang Schechinger, Kai-Chuan Chen, Zeljko Prijovic
  • Publication number: 20100129367
    Abstract: A number of human beta-glucuronidase variants having higher enzymatic activity at physiological pH as compared with wild-type beta-glucuronidase and uses thereof in prodrug therapy. Also disclosed herein is a method for identifying enzyme variants having elevated enzymatic activity using a mammalian surface display system.
    Type: Application
    Filed: November 25, 2009
    Publication date: May 27, 2010
    Applicant: Academia Sinica
    Inventors: Steve Roffler, Chia-Hung Wu, Wolfgang Schechinger, Kai-Chuan Chen, Zeljko M. Prijovic
  • Publication number: 20080176225
    Abstract: A recombinant DNA construct is provided and includes a first DNA fragment encoding a ?-glucuronidase and a second DNA fragment encoding a membrane anchoring domain. The ?-glucuronidase may be a human ?-glucuronidase or a mouse ?-glucuronidase. In one embodiment, an expression vector for delivering a gene of interest or portion thereof into a host cell includes a DNA sequence for the gene of interest, a first DNA fragment encoding a ?-glucuronidase, and a second DNA fragment encoding a membrane anchoring domain. In another embodiment, a method of introducing a gene of interest or portion thereof into a host cell is provided, including introducing into the host cell a recombinant DNA construct.
    Type: Application
    Filed: January 18, 2007
    Publication date: July 24, 2008
    Inventors: Steve ROFFLER, Tian-Lu Cheng, Yu-Cheng Su
  • Patent number: 7320791
    Abstract: A novel anti-polyethylene glycol monoclonal antibody and its preparation are disclosed. Such an antibody can be used for determining polyethylene glycol concentration in vitro or accelerating the clearance of a polyethylene glycol containing compound from the blood circulation in the human body thereby reducing the toxicity associated with the polyethylene glycol containing conjugate. The antibody is particularly useful in cancer therapy where the therapeutic agent is selectively delivered to the tumor by increasing the tumor/blood ratio of the polyethylene glycol containing compound.
    Type: Grant
    Filed: July 15, 2003
    Date of Patent: January 22, 2008
    Assignee: Academia Sinica
    Inventors: Steve Roffler, Tian-Lu Cheng, Pin-Yi Wu
  • Publication number: 20040014156
    Abstract: A novel anti-polyethylene glycol monoclonal antibody and its preparation are disclosed. Such an antibody can be used for determining polyethylene glycol concentration in vitro or accelerating the clearance of a polyethylene glycol containing compound from the blood circulation in the human body thereby reducing the toxicity associated with the polyethylene glycol containing conjugate. The antibody is particularly useful in cancer therapy where the therapeutic agent is selectively delivered to the tumor by increasing the tumor/blood ratio of the polyethylene glycol containing compound.
    Type: Application
    Filed: July 15, 2003
    Publication date: January 22, 2004
    Applicant: Academia Sinica
    Inventors: Steve Roffler, Tian-Lu Cheng, Pin-Yi Wu
  • Patent number: 6617118
    Abstract: A novel anti-polyethylene glycol monoclonal antibody and its preparation are disclosed. Such an antibody can be used for determining polyethylene glycol concentration in vitro or accelerating the clearance of a polyethylene glycol containing compound from the blood circulation in the human body thereby reducing the toxicity associated with the polyethylene glycol containing conjugate. The antibody is particularly useful in cancer therapy where the therapeutic agent is selectively delivered to the tumor by increasing the tumor/blood ratio of the polyethylene glycol containing compound.
    Type: Grant
    Filed: March 16, 2001
    Date of Patent: September 9, 2003
    Assignee: Academia Sinica
    Inventors: Steve Roffler, Tian-Lu Cheng, Pin-Yi Wu
  • Patent number: 6596849
    Abstract: A novel anti-polyethylene glycol monoclonal antibody and its preparation are disclosed. Such an antibody can be used for determining polyethylene glycol concentration in vitro or accelerating the clearance of a polyethylene glycol containing compound from the blood circulation in the human body thereby reducing the toxicity associated with the polyethylene glycol containing conjugate. The antibody is particularly useful in cancer therapy where the therapeutic agent is selectively delivered to the tumor by increasing the tumor/blood ratio of the polyethylene glycol containing compound.
    Type: Grant
    Filed: March 7, 2000
    Date of Patent: July 22, 2003
    Assignee: Academia Sinica
    Inventors: Steve Roffler, Tian-Lu Cheng, Pin-Yi Wu